Value proposition

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types.

Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing.

Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met.

Interested in joining our team? Please check out our jobs at
https://cariboubio.bamboohr.com/jobs/

Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, iPSC-derived NK cell therapies, and oncology